American Society of Hirudotherapy

ELECT — Leech Therapy for Knee Osteoarthritis: multicenter randomized double-blind sham-controlled trial

Lauche R, Cramer H, Klose P, Schmieder M, Michalsen A, Dobos G (2025) · Pre-registered protocol — Trials journal · n=240

RCT evidence detailTrial reference
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Khoshnevisan A 202280
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
multicenter (6 sites Germany, Switzerland, Austria), randomized, double-blind, sham-controlled trial
Sample size (n)
240
Intervention
Two sessions of 4-7 Hirudo medicinalis leeches periarticular knee, 28 days apart
Comparator
Sham application using leech-mimicking silicone device validated in Hohmann 2014 pilot
Primary endpoint
WOMAC pain at week 12 (pre-registered superiority margin: 8 points)
Primary result
Trial enrollment 78% complete as of 2026-Q1; planned interim analysis at week 12 follow-up of last patient (expected Q3 2026); full results published 2027
Follow-up duration
12 months (per protocol)

Key Findings

  • First multicenter, double-blind, sham-controlled RCT in hirudotherapy — methodological gold standard
  • Sham device based on Hohmann 2014 plantar fasciitis sham (validated blinding fidelity)
  • Powered to detect 8-point WOMAC pain difference at 80% power (n=240)
  • Pre-registered analysis plan reduces multiplicity concerns
  • 12-month follow-up addresses durability questions left open by Lauche 2014

Limitations

  • Results not yet available — primary endpoint scheduled Q3 2026
  • Sham fidelity from Hohmann 2014 (n=36) may not fully scale to multicenter execution
  • Six sites still all German-speaking — broader generalizability later
  • Protocol-driven only — no real-world pragmatic component
  • Some patients may infer allocation if leech-bite marks visible to clinician (cannot blind in all situations)

Clinical Implications

ELECT is the trial that will most likely settle the open question of whether hirudotherapy's effect on knee OA is biological or primarily expectancy. If superiority is demonstrated against sham at the pre-registered margin, the indication moves to GRADE 'high'. If non-superiority is found, the field will need to recalibrate around mechanism and patient-selection. Either outcome is field-defining. Clinicians should monitor publication (anticipated 2027) and update practice accordingly.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.